Search PubMed⌕ Search

PubMed · 189540

[Mediastinal chemodectoma (author's transl)].

Abstract

In 1958 a mediastinal tumor was discovered in an asymptomatic patient. She had previously complained of vomiting and an oesophageal abnormality had been discovered though not treated. The mediastinal tumor was resected and diagnosed as a non chromaffine chemodectoma. In the follow-up the mediastinal image never appeared normal and the heart shadow was enlarged. In 1974 an infiltrate appeared in the left lung. In 1975 the patient was operated : a pulmonary osteochondroma, a pericarditis and an intrapericardial aortopulmonary chemodectoma were discovered. The mediastinal chemodectoma is a rare tumor and its frequency, location and signs are discussed. The importance of angiography for diagnosis is stressed. The authors consider malignant degenerescence to be rare, and the treatment is surgical as the tumor is radioresistant. In the present case there was either a malignant recurrence or multiple focuses with a possible oesophageal location.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

L K Lacquet, A C Moulijn. 1976. [Mediastinal chemodectoma (author's transl)].. https://pubmed.ncbi.nlm.nih.gov/189540/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Hematometrocolpos in an adolescent female treated for pelvic Ewing sarcoma.

Radiation therapy is often used to achieve local control of pelvic Ewing sarcoma in children. The effects of radiation on the female reproductive tract have been well documented in adults with gynecological malignancies, but the long-term consequences of pelvic radiation in pre-pubertal or adolescent girls are not as well described. We report a case of hematometrocolpos developing in an adolescent previously treated with chemotherapy and radiation therapy for pelvic Ewing sarcoma. We describe the clinical presentation, radiographic features, gross pathology, treatment strategies, outcome, as well as putative predisposing factors and preventative interventions.

Bone Neoplasms↗

Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer.

BACKGROUND: Prostate cancer (PCa) and bone cell interactions are critical in the metastatic phase. Kallikrein 4 (KLK4/hK4) is expressed in both PCa and mineralized tissues. We determined if KLK4/hK4 expression was associated with, and influenced by, the bone environment of metastatic PCa. METHODS: Immunohistochemistry, in vitro co-culture, cell migration, and attachment assays. RESULTS: hK4 was localized to tumor cells and osteoblasts in bone metastases. KLK4/hK4 increased in LNCaP and PC3 cells co-cultured with SaOs2 cells; SaOs2 KLK4/hK4 was unchanged. Co-culture did not affect cell proliferation but altered alkaline phosphatase activity/mRNA levels in SaOs2 cells. KLK4-transfected PC3 cells had increased migration towards SaOs2 conditioned medium and greater attachment to the bone-matrix proteins, collagens I and IV. CONCLUSIONS: hK4 expression and interaction with both tumor cells and osteoblasts suggests a role for hK4 in PCa bone metastasis. Whether this observation is unique to bone metastasis or reflects a role for hK4 in PCa metastasis generally is yet to be established.

Bone Neoplasms↗